10/11/2024 - Here is a new SELL breakout chosen mechanically:10/11/2024 - Here is a new SELL breakout chosen mechanically:
Stop @ $21.31
Entry SELL @ $19.78 or less
Target @ $17.24
FMEA trade ideas
FME • Fresenius Medical Care • LONG#FME • Fresenius Medical Care • XETRA LONG TF H4
TP = 45.35 , SL = 39.59
The trend continues, the nearest support level according to my calculations TP 45.35
ABC/DTarget is D.
Possible stop under C.
I own this and it is a slow but a steady mover.
I scooped this up very close to the bottom and have not been disappointed.
Not yet anyway LOL.
The market has a way of biting me when I least expect it but I plan to hang.
No recommendation.
ATH 57.94
EARNINGS 8-2/ESTIMATED.
Fresenius Medical Care AG & Co. KGaA provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Cup and HandleResistance overhead from a prior gap down. OVERBOUGHT using standard RSI set at 70.
Cup low is 12.79.
Earnings 5-9-23.
This company is in Germany and provides dialysis to kidney failure patients. There are clinics al over the US owned by this company providing a service that kidney failure patients can not live without.
No recommendation.
52 Week Range
12.79
34.65
Day Range
21.52
21.69
EPS (FWD)
1.86
PE (FWD)
11.54
Div Rate (TTM)
$0.71
Yield (TTM)
3.30%
Short Interest
-
Market Cap
$12.61B
Fresenius Medical Care AG & Co. KGaA provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Bottom FishingAscending Triangle.
ATL is 3.35.
3 year low is 12.79 which was made recently.
ATH 57.94.
Another dialysis company that is not based in the USA, so as a rule there would be no dividend.
Dialysis is not going away unfortunately and these dialysis sessions 3 times a week will always be covered as far as I can see.
I worked in this field and the patients consist of folks with a diagnosis of hypertension and diabetes for the most part, but not always. I would see an occasional glomerulonephritis etc.
Most of the patients in this area were non-compliant (not all) and there was a definite race domination to the point of 90%. This may be different in another region versus the southeast.
No recommendation.
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
$FMS with a Bearish outlook following its earnings #Stocks The PEAD projected a Bearish outlook for $FMS after a Negative Under reaction following its earnings release placing the stock in drift D with an expected accuracy of 33.33%.
$FMS with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $FMS after a Positive over reaction following its earnings release placing the stock in drift B with an expected accuracy of 71.43%.
Long FME After Earnings ReportHi Traders!
𝗧𝗵𝗲 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝘀𝗵𝗮𝗿𝗲𝗱 𝗶𝗻 𝘁𝗵𝗶𝘀 video 𝗶𝘀 𝗻𝗼𝘁 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗮𝗱𝘃𝗶𝗰𝗲.
𝗔𝗹𝘄𝗮𝘆𝘀 𝗰𝗼𝗻𝗱𝘂𝗰𝘁 𝘆𝗼𝘂𝗿 𝗼𝘄𝗻 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗮𝗻𝗱 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵.
Happy trading!
FMC Trade with MOUNT Germany 30 Quant SystemTrading is Waiting - Quants have a lot of time and wait until they the setup fits their requirements.
Traderama uses quant based "buy the valley" strategies for equity trading. This is an example, that the best returns will be achieved if you find the bottom and trade the bounce.
This trade example is a result of the MOUNT Quant System
FMS Technical Analysis 🧙Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients in roughly 4,000 clinics across the globe as of December 2019. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly
If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
Pull Back (Bottom) FishingThis is a stock in healthcare and is in the dialysis field. It appears they missed earnings or gave grim guidance. Dialysis is grim, take my word for it )o:
Located in Germany but the clinics are in the US, and not a lot of competition. DVA is one that I know of.
Extremely oversold..
There has been extreme selling pressure indicated by being below the bollinger bands set at an 80 MA verses a 20 and 3 standard deviation verses 2. When there are no sellers left, which appears to be getting close, chances are, this will move up.
Bollinger bands are great and I do not think I could chart without them on TOS. Lots do not like the bands, we are all different. They move with price and get wide when volatility occurs and narrow when price is gonna pop one way or the other. The bands tell a lot about what is going on.
Gappy chart and I am not sure it is finished pulling back. If anyone is in the healthcare field, then we know dialysis is not going away, unfortunately.
Not a recommendation..just an observation.
Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides pharmacy services, vascular, cardiovascular, endovascular specialty, hospitalist, emergency, intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2019, it operated 3,994 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
V Bottom V CupEarnings were 7-30 Has broken from cup and handle pattern. No rising wedges noted
I was looking for something "safe" for my IRA. I know in the market nothing is really safe, but this is a dialysis company. Dialysis is not going away and my first job as a nurse was in a dialysis clinic. Buffet says stay with stuff you know (o:
Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides pharmacy services, vascular, cardiovascular, endovascular specialty, hospitalist, emergency, intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2019, it operated 3,994 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Fresenius Medical upgraded to Buy from Hold at JefferiesFresenius Medical upgraded to Buy from Hold at Jefferies. Jefferies analyst James Vane-Tempest upgraded Fresenius Medical Care to Buy from Hold with a $44.50 price target. The company's homecare strategy is being underestimated by the market and the roll out of NxStage dialysis products could drive shareholder value, Vane-Tempest tells investors in a research note. The analyst believes Fresenius Medical is among the stocks in European Healthcare that could double over the next five years. source thefly
FME - XETRAI am focus to set right target profit by using stop sell order. There is no technical level I am happy with.
